Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib versus best available therapy in high-risk polycythaemia vera or essential thrombocythaemia resistant or intolerant to hydroxycarbamide
ISRCTN61925716Phase 2Completed
- Sponsor
- University of Birmingham
- Start
- Jun 2012
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of ruxolitinib in polycythemia vera (PV) and thrombocythemia (2 arms), sponsored by University of Birmingham. Primary endpoint: Complete response rate within 1 year. Started Jun 2012; status: completed.
02
Drugs
03
Conditions
polycythemia vera (PV)thrombocythemia
Beyond the preview
Go deeper on ISRCTN61925716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN61925716.